NANOBIOTIX 31.080 € (+3,74 %)
SERGEFERRARI GROUP 8.000 € (+2,56 %)
TOTALENERGIES 68.360 € (-1,31 %)
SERGEFERRARI GROUP 8.000 € (+2,56 %)
ADYEN 824.900 € (+0,37 %)
EXAIL TECHNOLOGIES 116.700 € (+25,28 %)
CAPGEMINI 89.680 € (+1,33 %)
SHELL PLC 33.700 € (-1,00 %)
BUREAU VERITAS 26.120 € (+0,66 %)
HERMES INTL 1 626.000 € (+0,77 %)
PHILIPS KON 23.890 € (-0,17 %)
SANOFI 75.070 € (+1,78 %)
ASML HOLDING 1 578.200 € (-0,99 %)
BOLLORE 4.100 € (+0,15 %)
VEOLIA ENVIRON. 36.230 € (+0,22 %)
SMCP 5.015 € (+0,30 %)
FLOW TRADERS 25.580 € (-0,93 %)
ASM INTERNATIONAL 948.000 € (-4,34 %)
AYVENS 11.460 € (-0,87 %)
CSG 12.682 € (+2,69 %)
BE SEMICONDUCTOR 282.700 € (-2,21 %)
SCOR SE 31.980 € (+0,50 %)
STMICROELECTRONICS 62.580 € (-3,81 %)
ESSILORLUXOTTICA 168.650 € (+1,54 %)
CRCAM TOURAINE CCI 138.500 € (-0,93 %)
LISI 66.100 € (-0,15 %)
LVMH 495.750 € (+0,27 %)
BOUYGUES 49.750 € (-0,78 %)
DSM FIRMENICH AG 79.980 € (-0,65 %)
NEXANS 141.100 € (-3,75 %)
STELLANTIS NV 5.024 € (-1,95 %)
THALES 216.500 € (-0,87 %)
UMG 18.355 € (+0,71 %)
NN GROUP 76.320 € (-0,29 %)
AHOLD DEL 35.430 € (+0,85 %)
2CRSI 27.520 € (+8,01 %)
SODEXO 51.250 € (-0,10 %)
SOITEC 114.350 € (+1,87 %)
TKH GROUP 43.620 € (+1,73 %)
LNA SANTE 34.000 € (+3,03 %)
OVH 13.600 € (+1,49 %)
BAM GROEP KON 12.550 € (-1,18 %)
AMG 32.900 € (-1,56 %)
EUROFINS SCIENT. 68.960 € (+1,00 %)
CEGEDIM 11.040 € (-1,43 %)
AALBERTS NV 38.980 € (-1,66 %)
DANONE 72.120 € (+3,06 %)
ALSTOM 15.380 € (-1,94 %)
REXEL 36.860 € (-1,18 %)
RELX 27.440 € (-0,29 %)
HAFFNER ENERGY 0.217 € (-2,25 %)
ERAMET 45.160 € (-1,40 %)
SAINT GOBAIN 80.600 € (-1,42 %)
BNP PARIBAS ACT.A 101.120 € (-1,83 %)
RUBIS 31.540 € (+0,64 %)
JCDECAUX 19.050 € (+1,33 %)
PERNOD RICARD 65.960 € (-0,06 %)
SAVENCIA 66.600 € (0,00 %)
AIRBUS 191.900 € (-1,63 %)
ALTEN 53.400 € (+1,81 %) |
27/06/2026 00:05
EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing lossEQS-News: EAN Congress / Key word(s): Miscellaneous GENEVA, June 27, 2026 /PRNewswire/ -- Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of developing dementia than those who do not, according to new research presented at the European Academy of Neurology (EAN) Congress 2026. Hearing loss is widely recognised as the largest modifiable risk factor for dementia. Yet whether hearing aids can reduce dementia risk remains debated. To explore this, researchers from University Hospital Zurich and the University of Liverpool analysed electronic health records from more than 250 million patients in the TriNetX network. They compared adults with hearing loss who used hearing aids with closely matched adults who did not. The analysis included the overall hearing-loss population as well as people living with epilepsy, stroke, type 2 diabetes, chronic kidney disease, heart failure, migraine and osteoarthritis. No significant association was found between hearing aid use and dementia risk in the overall population with hearing loss, nor among people with stroke, migraine, type 2 diabetes, chronic kidney disease, heart failure or osteoarthritis. However, among adults with both epilepsy and hearing loss, hearing aid use was associated with a 23% lower risk of dementia. This corresponded to an absolute risk reduction of 2.7 percentage points over five years, equivalent to one fewer case of dementia for every 37 people using hearing aids. The researchers believe the findings may be explained by differences in cognitive reserve – the brain's ability to continue functioning effectively despite age-related changes or damage caused by disease. Lead author Dr Carolina Ferreira-Atuesta explained: "Most people with hearing loss have enough cognitive reserve to absorb the extra effort caused by hearing impairment, so correcting it may not have a large effect on dementia risk. Epilepsy is different because cognitive reserve is often already reduced, meaning that removing one additional source of strain may have a greater impact." "There are several biologically plausible reasons why we might see this effect in epilepsy. The condition is associated with accelerated cognitive decline, temporal lobe epilepsy affects areas of the brain involved in hearing and some anti-seizure medications may worsen hearing," added Dr Ferreira-Atuesta. The findings have important implications for clinical practice, according to the researchers. Since people with epilepsy are already in regular contact with healthcare services, hearing assessments could be readily incorporated into routine care.
![]() 27.06.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group. 2355238 27.06.2026 CET/CEST Source : Webdisclosure.com |
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière
